CD16a-Binding Agents for Low-Affinity Genotypes and NK Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing monoclonal antibody therapies face reduced therapeutic efficacy due to ineffective interactions with low-affinity forms of the CD16a receptor, leading to suboptimal recruitment of immune cells such as NK cells, particularly in subjects with homozygous or heterozygous low-affinity CD16a genotypes.
Innovation Solution
Development of CD16a-binding agents, such as small molecule compounds or conjugates, that enhance binding to both high- and low-affinity forms of the CD16a receptor, thereby improving the recruitment and activation of immune cells like NK cells, even in subjects with low-affinity genotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody therapies are used to treat diseases, then therapeutic effects are achieved, but efficacy is reduced in subjects with low-affinity CD16a genotypes
Solution Approach 1:
The patent modifies the antibody structure by engineering the Fc region to alter its binding parameters to CD16a receptors. Specifically, mutations in the Fc region (such as L234A, L235A, N297Q) change the affinity and interaction characteristics of the antibody with CD16a, enabling enhanced binding to both high-affinity and low-affinity CD16a forms across different genotypes
Solution Approach 2:
The patent creates composite antibody structures by combining mutated Fc regions with specific variable regions. These engineered antibodies integrate multiple functional elements: the antigen-binding variable regions and the modified Fc regions with enhanced CD16a binding, creating a composite therapeutic agent that overcomes genotype limitations
2Productivity
If Fc receptor binding is enhanced through antibody engineering, then immune cell recruitment is improved, but complexity of antibody structure increases
Solution Approach 1:
The patent divides the antibody into distinct functional segments: the variable regions (VH and VL) responsible for antigen binding and the Fc region responsible for immune effector functions. By independently engineering the Fc region with specific mutations while keeping the variable regions intact, the patent enhances immune cell recruitment without compromising antigen specificity
Solution Approach 2:
The patent applies localized modifications specifically to the Fc region of the antibody rather than throughout the entire structure. Mutations are introduced at specific positions (such as L234, L235, N297) within the Fc region to enhance CD16a binding, while the rest of the antibody structure remains unchanged, maintaining simplicity where possible
Data Source
AI summary
Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.